The Primary Study Of Serum Differential Expression Protein By SELDI-TOF-MS In Non-Hodgkin Lymphoma

Objective To find differential expression protein by proteomic technology in non-Hodgkin lymphoma(NHL) and healthy controls.Methods Thirty-eight patients of NHL, including 47 male and 25 female, are from the Tumor Hosptal of ShanXi. The ages are from 11 to 83, mean age is 52.5. Thirty-two healthy persons, selected from physical examination, are control group including 17 male and 15 female. The ages are from 10 to 74, mean age is 26.5. Serum serum from 72 patients of non-Hodgkin lymphoma(NHL) and 32 healthy controls were detected by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF-MS) by using WCX-2 PorteinChip. Ciphergen softwere, Biomarker Wizard, was used to identify proteomic features.Results We rapidly identified a number of potential candidate proteins involved in non-Hodgkin lymphoma (NHL) by proteomic technology. These included the peak intensity of 3193Da,3398Da,7974Da,8564Da,8692Da and 15934Da. There are five differentially expressed protein markers between 72 NHL patients and 32 healthy volunteers. Their relative molecular weights are 3193Da, 3398Da, 8564Da, 8692Da and 15938Da. The protein marker of 15938Da are high level in patients, and meanwhile are low level in healthy volunteers. The protein markers of 3193Da, 3398Da, 8564Da and 8692Da are low level in patients, and meanwhile are high level in healthy volunteers.Conclusion SELDI-TOF-MS ProteinChip technology is a quick easy and convenient, and high-throughput analyzing method which can screen several relatively specific protein markets from the blood serum of NHL patients. These peaks of 3193Da,3398Da,7974Da,8564Da,8692Da and 15934Da are potential biomarkers for the diagnosis of non-Hodgkin lymphoma (NHL). It is likely a complementary method for the diagnosis of non-Hodgkin lymphoma (NHL).